



Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application (old metric)	Date Site Invited (new metric)	Date Site Selected (new metric)	HRA Approval Date (new metric)	Date Site Confirmed By Sponsor (new metric)	Date Site Confirmed (new metric)	Date Site Ready to Start (new metric)	Date of First Patient Recruited	Non-Confirmation Status (new metric)	Duration between VRA / Date site selected and First Patient (days)	Benchmark Met	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:		
15/LO/1302	169660	HRA Light	OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study Randomised, Phase II Umbrella Trial of a Weekly Paclitaxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer		11/11/2016	09/01/2017	07/06/2016	03/05/2017	17/05/2017	07/06/2017				No												Internal capacity issues.	NHS Provider	
15/EE/0421	191851	HRA Light	Pomalidomide in relapsed and refractory multiple myeloma		13/03/2017	30/03/2017	18/08/2016	24/04/2017	04/05/2017	08/06/2017				No				Y	Y							Delays receiving study drug and lab kits at site.	Both	
BIO/MIL/01	135437	HRA Light	MILES - UK: Post Marketing, Multicenter, Single Arm, Observational Clinical Registry to Evaluate Safety and Efficacy of BioMime Sirolimus Eluting Stent System In All Comers Real World Population With Coronary Artery Stenosis in United Kingdom.		22/02/2017	10/05/2017	28/07/2016							Within timeframe														
15/NW/041	167060	HRA Light	A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenolidomide and bortezomib.		07/03/2017	06/04/2017								No												Delay due to additional contract with Myeloma UK - caused by both NHS Provider and Myeloma UK.	NHS Provider	